Patents by Inventor Roman Fleck

Roman Fleck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230265055
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer, hematological cancer, and pancreatic cancer.
    Type: Application
    Filed: September 3, 2021
    Publication date: August 24, 2023
    Inventors: Roman FLECK, John PROUDFOOT, Jeff OMEARA, Patrick Thomas GUNNING, Ahmed Magdy ALI, David Alexander ROSA, Angel Sampedro PALERM, Alla DARWISH, Alford Antoine JOHN
  • Publication number: 20230159445
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: May 25, 2023
    Inventors: Roman FLECK, John PROUDFOOT, Jeff OMEARA, Krishna Kumar GNANASEKARAN, Patrick Thomas GUNNING, Alford Antoine JOHN, Angel Sampedro PALERM, Alla DARWISH, Dziyana KRASKOUSKAYA, Ahmed Magdy Ahmed Mohamed ALI
  • Publication number: 20230150946
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: May 18, 2023
    Inventors: Roman FLECK, John PROUDFOOT, Krishna Kumar GNANASEKARAN, Patrick Thomas GUNNING, Alford Antoine JOHN, Angel Sampedro PALERM, Alla DARWISH, Dziyana KRASKOUSKAYA
  • Publication number: 20230137956
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: May 4, 2023
    Inventors: Roman FLECK, John PROUDFOOT, Jeff OMEARA, Patrick Thomas GUNNING, Angel Sampedro PALERM, Alla DARWISH, Dziyana KRASKOUSKAYA
  • Publication number: 20080008720
    Abstract: Disclosed are substituted tricyclic heterocycle compounds of the formulas (I), (II) and (III) shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds.
    Type: Application
    Filed: August 9, 2007
    Publication date: January 10, 2008
    Inventors: Charles Cywin, Roman Fleck, Eugene Hickey, Weimin Liu, Tina Morwick, John Proudfoot, Denice Spero
  • Publication number: 20050288285
    Abstract: Disclosed are compounds of formula (I): wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the I?B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
    Type: Application
    Filed: August 18, 2005
    Publication date: December 29, 2005
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles Cywin, Zhidong Chen, Roman Fleck, Ming-Hong Hao, Eugene Hickey, Weimin Liu, Daniel Marshall, Peter Nemoto, Ronald Sorcek, Sanxing Sun, Jiang-Ping Wu, Tina Morwick, Jonathan Emeigh
  • Publication number: 20050203158
    Abstract: Disclosed are substituted benzimidazole compounds of formula (I): wherein R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: August 1, 2003
    Publication date: September 15, 2005
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Joerg Bentzien, Brian Cook, Charles Cywin, Roman Fleck, Ho Lo, Peter Nemoto, Steven Pullen, Gregory Roth, Roger Snow, Hidenori Takahashi, Ji Wang, Kevin Moriarty, Lei Qiao, Michael Winters
  • Publication number: 20050101601
    Abstract: Disclosed are substituted tricyclic heterocycle compounds of the formulas (I), (II) and (III) shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds.
    Type: Application
    Filed: October 7, 2004
    Publication date: May 12, 2005
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles Cywin, Roman Fleck, Eugene Hickey, Weimin Liu, Tina Morwick, John Proudfoot, Denice Spero